60 results about "Hormone therapy" patented technology

Methods for treating certain cancers in patients, such as mammals, using certain 17α-hydroxylase/C_17,20-lyase inhibitors are discussed herein. More particularly, methods for treating cancers comprising administering a 17α-hydroxylase/C_17,20-lyase inhibitor, such as abiraterone acetate (i.e. 3β-acetoxy-17-(3-pyridyl) androsta-5,16-diene) and metabolites thereof are described. In addition, methods for treating cancers that are refractory to hormone therapy or that are refractory to chemotherapy are also discussed. Finally novel dosing regimens and novel uses of the compounds discussed herein are disclosed.

The invention relates to an anti-sensitization and restoration external preparation for skin, belonging to the technical field of Chinese medicinal preparations. Based on the research and treatment principle of the pathogenic mechanism of skin impairment aggravation of a patient caused by sensitive or allergic dermatitis and hormone therapy sensitive or allergic dermatitis according to the traditional Chinese medicine and in combination with other component raw materials, active ingredients contained in the preparation have the effects of clearing away heat and toxic materials, resisting sensitization, restoring, converging and increasing skin elasticity and luster. The preparation can be prepared into cream or water aqua. The anti-sensitization and restoration external preparation is directly applied to the infection focuses of the patient, has no toxic or side effect, has a good curative effect, is easy to use, and is suitable for the patient suffering from skin impairment caused bysensitive or allergic dermatitis and hormone therapy sensitive or allergic dermatitis; and the problems of larger skin impairment of the patient caused by the conventional hormone therapy of sensitive or allergic dermatitis, difficulty in treating and poor curative effect are solved.

Methods and pharmaceuticals for inhibiting or preventing metastasis formation in animals, including humans, having primary tumors, through the administration of phosphorothioates including their thiol and disulfide metabolites are disclosed. These compounds stimulate angiostatin levels, inhibit matrix metalloproteinases (MMPs), and stimulate manganese superoxidase dismutase (MnSOD). Phosphorothioates, of which amifostine is an example, can be administered as a combination therapy with traditional cancer therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy and gene-therapy. Inhibition or prevention of metastasis by phosphorothioates is independent of tumor type, including adenocarcinomas and sarcomas.

The present invention provides a traditional Chinese medicine preparation for treating importence, which is the prepared slice comprising the following medicinal materials: 20-180 parts by weight of Astragalus root; 15-30 parts by weight of Chinese angelica; 15-30 parts by weight of pilose asiabell root or 15-20 parts by weight of ginseng; 15-30 parts by weight of white peony root; 6-15 parts by weight of actynolin; 2-3 parts by weight of centipede; 10-15 parts by weight of shorthorned epimedium herb; 10-15 parts by weight of dodder seed; 15-30 parts by weight of common cnidium fruit; 6-15 parts by weight of chuanxiong rhizome; 6-15 parts by weight of nutgrass galingale rhizome; 3-5 parts by weight of powdered antler or 0.5-1.5 parts by weight of hairy antler; and 6-10 parts by weight of liquorice. The Chinese medicine preparation for treating importenance according to the invention applies the method of general nourishment on the basis of the theory of traditional Chinese medicine for regulating the dysfunction of meridian of human organ and the unsmooth running of qi-blood and body fluid. The invention overcomes the defect of unremarkable effect when the method of temperature compensation is singly applied for treating the asynodia according to the traditional Chinese medicine. Simultaneously the side effect caused by singly adopting vasodilation or hormone therapy according to the western medicine. The traditional Chinese medicine of the invention has the characteristics of quick curative effect, no toxic or side effect, flexible theory and radical treatment. Simultaneously according to the principle of treating the root of the disease in the theory of traditional Chinese medicine, the medicine is added or reduced according to the illness state on the basis of general nourishment for adopting the symptoms of different patients or the illness states of a same patient in different periods.

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

The present invention provides an effective, all-natural, non-toxic, non-hormonal composition consisting of vitamin D3, vitamin E, selenium, green tea extract, saw palmetto berry extract, isoflavanoids, and lycopene for prostate health. The invention provides compositions and methods to prevent, alleviate, and/or treat symptoms associated with prostate conditions and diseases. The prostate health composition may be used to supplement medical treatment such as radiation therapy, chemotherapy, and hormone therapy.

Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.).

The present invention relates to a method for treating prostate cancer, which comprises administering an anti-CTLA4 antibody, or an antigen-binding portion thereof, especially a human antibody against human CTLA4, such as antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2 , 4.13.1, 4.14.3, 6.1.1, ticilimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also known as MDX-101 and 10D1) , in combination with hormone therapy. Hormone therapy agents include, inter alia, antiandrogens (e.g., megestrol, cyproterone, flutamide, nilutamide, and bicalutamide), GnRH antagonists (e.g., ababa Rick and histrelin), and LH-RH agonists (eg, leuprolide, goserelin, and buserelin). The present invention relates to neoadjuvant therapy, adjuvant therapy, treatment of elevated PSA, first-line treatment, second-line treatment and third-line treatment of localized or metastatic prostate cancer.

The invention relates to an application of ginsenoside in the preparation of medicine for treating osteoporosis, and the osteoporosis is glucocorticoid-induced osteoporosis. The advantages of the present invention are: the present invention provides a new application of ginsenosides, which broadens the medicinal scope of ginsenosides; At the same time, it can effectively prevent and treat glucocorticoid-induced osteoporosis, and reduce the osteoporosis caused by hormone therapy in patients; Better treatment for patients with steroid-induced osteoporosis.

The present invention is directed to neutralizing prolactin receptor antibodies 002-H06 and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and/or prevention of anemia in patients with dysfunctional uterine bleeding. Compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.

To provide means for treating and preventing a wide variety of cancers and tumors, including cancer in which there is PI3K/Akt pathway activation or p53 deactivation, or tumors for which chemotherapy, radiation therapy, hormone therapy, and other such conventional treatment methods have low effectiveness, different molecularly targeted drugs such as OBP-801 and PI3K inhibitor—preferably LY294002, BKM120, GDC-0941, BEZ235, BYL719, or CH5132799—are used in combination. This makes it possible to simultaneously obtain a plurality of different marked pharmaceutical benefits which are synergistic, not being obtainable through use of a formulation with either of the respective molecularly targeted drugs alone, such as caspase pathway activation, enhanced expression of Bim, increased accumulation of intracellular reactive oxygen species, and suppressed expression of survivin and XIAP protein, and makes it possible to provide new and clinically effective tumor treatment/prevention strategies.

The invention discloses a medicament for treating hysteromyoma. The medicament mainly comprises the following components in part by weight: 20 to 30 parts of white peony root, 20 to 30 parts of red peony root, 15 to 20 parts of safflower, 20 to 25 parts of angelica, 15 to 20 parts of tuber fleeceflower, 20 to 30 parts of burreed tuber, 20 to 30 parts of zedoary, 20 to 30 parts of fresh aloe, 20 to 30 parts of prepared rehmannia root, 20 to 25 parts of medlar and 20 to 25 parts of herba lycopi leaf; and the medicament is prepared by a common method. Clinical medicament effect tests show that the medicament has the advantages of quick response, good effect, avoidance of operation, no pain, no wound, no side effect caused by hormone therapy and low treatment cost.

An ophthalmic instillation composition which contains melatonin and at least one other hormone, typically an estrogen but also possibly testosterone or another aromatasable androgen. The instillation is designed to reduce or eliminate cataracts in men or women to which such an ophthalmic instillation composition is administered.

The invention discloses a placental extract biological gel preparation for treating premature ovarian failure and a preparation method thereof. The placental extract biological gel preparation is prepared from a gel substrate and placental extract serving as an active ingredient, wherein the volume of the placental extract is 90 to 99.5% of that of the biological gel preparation. According to the placental extract biological gel preparation disclosed by the invention, the placental extract is utilized as the active ingredient and obtained by being purified by multistep of technologies; not only are effective ingredients of collagen, polypeptide, varieties of growth factors and the like in placenta kept, but also no cell component is contained, and the problems of safety and immunological rejection of cell preparation are solved. The preparation is favorable for promoting ovarian function reconstruction of a premature ovarian failure patient, has a very good premature ovarian failure treating effect, avoids oral hormone therapy and hormone dependence, utilizes mucosa transdermal absorption playing action, can be fully absorbed, avoids injection and has better safety.